International Journal of Infectious Diseases
Volume 16, Issue 3 , Pages e209-e215 , March 2012

Early impact of pneumococcal conjugate vaccine on invasive pneumococcal disease in Singapore children, 2005 through 2010

  • Koh Cheng Thoon

      Affiliations

    • Infectious Disease Service, Department of Paediatrics, KK Women's and Children's Hospital, 100 Bukit Timah Road, 229899, Singapore
    • Corresponding Author InformationCorresponding author. Tel.: +65 6394 8408; fax: +65 6394 1973.
    • ,
  • Chia Yin Chong

      Affiliations

    • Infectious Disease Service, Department of Paediatrics, KK Women's and Children's Hospital, 100 Bukit Timah Road, 229899, Singapore
    • ,
  • Nancy Wen Sim Tee

      Affiliations

    • Department of Pathology and Laboratory Medicine, KK Women's and Children's Hospital, Singapore

Received 16 March 2011 ,Revised 1 July 2011 ,Accepted 30 November 2011.

References 

  1. Dagan R. New insights on pneumococcal disease: what we have learned over the past decade. Vaccine. 2009;27(Suppl 3):C3–C5
  2. Low S, Chan FL, Cutter J, Ma S, Goh KT, Chew SK. A national study of the epidemiology of pneumococcal disease among hospitalised patients in Singapore: 1995 to 2004. Singapore Med J. 2007;48:824–829
  3. Chong CY, Thoon KC, Mok YH, Tee NW. Invasive pneumococcal disease in Singapore children. Vaccine. 2008;26:3427–3431
  4. Ministry of Health. Medisave for Chronic Disease Management Programme (CDMP) and vaccinations. Ministry of Health, Singapore; November 3, 2011. Available at: http://www.moh.gov.sg/content/moh_web/home/policies-and-issues/elderly_healthcare.html (accessed December 24, 2011).
  5. Bell SM. The CDS disc method of antibiotic sensitivity testing (calibrated dichotomous sensitivity test). Pathology. 1975;7:1–48
  6. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. M100-S14. Wayne, PA: NCCLS; 2004.
  7. Department of Statistics. Population trends 2010. Singapore: Department of Statistics, Ministry of Trade and Industry; September 2010. Available at: http://www.singstat.gov.sg/pubn/popn/population2010.pdf (accessed October 13, 2010).
  8. Department of Statistics. Census of population 2010—advanced census release. Singapore: Department of Statistics, Ministry of Trade and Industry; August 2010. Available at: http://www.singstat.gov.sg/pubn/popn/c2010acr.pdf (accessed October 13, 2010).
  9. Health Promotion Board. National Immunisation Registry. Singapore Government; August 11, 2007. Available at: http://www.nir.hpb.gov.sg/nir/sv/eservices/eservicesv?ACTION=DISPLAY_ABOUTUS (accessed October 16, 2010).
  10. Dean AG, Sullivan KM, Soe MM. OpenEpi: open source epidemiologic statistics for public health, version 2.3.1. Updated September 19, 2010. Available at: http://www.OpenEpi.com (accessed June 6, 2011).
  11. Calbo E, Diaz A, Canadell E, Fábrega J, Uriz S, Xercavins M, et al. Invasive pneumococcal disease among children in a health district of Barcelona: early impact of pneumococcal conjugate vaccine. Clin Microbiol Infect. 2006;12:867–872
  12. Muñoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis. 2008;46:174–182
  13. Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein–polysaccharide conjugate vaccine. N Engl J Med. 2003;348:1737–1746
  14. Pilishvilli T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201:32–41
  15. Vestrheim DF, Løvoll Ø, Ingeborg S, Caugant DA, Høiby EA, Bakke H, et al. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccine in Norway. Vaccine. 2008;26:3277–3281
  16. Deceuninck G, De Wals P, Bouliannne N, De Serres G. Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule in Quebec, Canada. Pediatr Infect Dis J. 2010;29:546–549
  17. Health Protection Agency. Invasive pneumococcal disease (IPD) in England & Wales after 7-valent conjugate vaccines (PCV7); potential impact of 10 and 13-valent vaccines. UK: HPA; June 24, 2009. Available at: http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1245581527892 (accessed October 27, 2010).
  18. Roche PW, Krause V, Cook H, Barralet J, Coleman D, Sweeny A, et al. Invasive pneumococcal disease in Australia, 2006. Commun Dis Intell. 2008;32:18–30
  19. Haber M, Barskey A, Baughman W, Barker L, Whitney CG, Shaw KM, et al. Herd immunity and pneumococcal conjugate vaccine: a quantitative model. Vaccine. 2007;25:5390–5398
  20. Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case–control study. Lancet. 2006;368:1495–1502
  21. Mahon BE, Hsu K, Karumuri S, Kaplan SL, Mason EO, Pelton SI. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens. Vaccine. 2006;24:2514–2520
  22. Hicks LA, Harrison LH, Flannery B, Hadler JL, Schaffner W, Craig AS, et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998–2004. J Infect Dis. 2007;196:1346–1354
  23. Pai R, Moore MR, Pilishvili T, Gertz RE, Whitney CG, Beall B. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis. 2005;192:1988–1995
  24. Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis. 2010;14:e197–e209
  25. Reinert RR, Jacobs MR, Kaplan SL. Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development. Vaccine. 2010;28:4249–4259
  26. Hsieh YC, Lin PY, Chiu CH, Huang YC, Chang KY, Liao CH, et al. National survey of invasive pneumococcal diseases in Taiwan under partial PCV7 vaccination in 2007: emergence of serotype 19A with high invasive potential. Vaccine. 2009;27:5513–5518
  27. Choi EH, Kim SH, Eun BW, Kim SJ, Kim NH, Lee J, et al. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis. 2008;14:275–281
  28. Huang SS, Hinrichsen VL, Stevenson AE, Rifas-Shiman SL, Kleinman K, Pelton SI, et al. Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics. 2009;124:e1–e11
  29. Dagan R, Melamed R, Muallem M, Piglansky L, Greenberg D, Abramson O, et al. Reduction of nasopharyngeal carriage of pneumococci during the second year of life by a heptavalent conjugate pneumococcal vaccine. J Infect Dis. 1996;174:1271–1278
  30. van Gils EJ, Veenhoven RH, Hak E, Rodenburg GD, Keijzers WC, Bogaert D, et al. Pneumococcal conjugate vaccination and nasopharyngeal acquisition of pneumococcal serotype 19A strains. JAMA. 2010;304:1099–1106
  31. Weinberger DM, Trzciński K, Lu YJ, Bogaert D, Brandes A, Galagan J, et al. Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog. 2009;5:e1000476
  32. Dagan R, Givon-Lavi N, Leibovitz E, Greenberg D, Porat N. Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J Infect Dis. 2009;199:776–785
  33. Greenberg D, Givon-Lavi N, Sharf AZ, Vardy D, Dagan R. The association between antibiotic use in the community and nasopharyngeal carriage of antibiotic resistant Streptococcus pneumoniae in Bedouin children. Pediatr Infect Dis J. 2008;27:776–782
  34. Flannery B, Shrag S, Bennet NM, Lynfield R, Harrison LH, Reingold A, et al. Impact of childhood vaccination on racial disparities in invasive Streptococcus pneumoniae infections. JAMA. 2004;291:2197–2203
  35. Department of Statistics. Census of population 2010: key indicators of the resident population and resident households. Singapore: Department of Statistics, Ministry of Trade and Industry; February 2011. Available at: http://www.singstat.gov.sg/pubn/popn/c2010sr3/indicators.pdf (accessed December 24, 2011).
  36. Lin TY, Shah NK, Brooks D, Garcia CS. Summary of invasive pneumococcal disease burden among children in the Asia-Pacific region. Vaccine. 2010;28:7589–7605
  37. Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med. 2006;354:1455–1463
  38. Li ST, Tancredi D. Empyema hospitalizations increased in US children despite pneumococcal conjugate vaccine. Pediatrics. 2010;125:26–33
  39. Fletcher M, Leeming J, Cartwright K, Finn A. Childhood empyema: limited potential impact of 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2006;25:559–560
  40. Strachan R, Jaffé A. Assessment of the burden of paediatric empyema in Australia. J Paediatr Child Health. 2009;45:431–436
  41. Garau J, Calbo E. Capsular types and predicting patient outcomes in pneumococcal bacteremia. Clin Infect Dis. 2007;45:52–54

☆ This paper was presented in part as an oral presentation at the 12th Western Pacific Congress on Chemotherapy and Infectious Diseases, Singapore, December 2–5, 2010, under the title “Impact of conjugate pneumococcal vaccine coverage and invasive pneumococcal disease incidence in Singapore children”.

PII: S1201-9712(12)00002-1

doi: 10.1016/j.ijid.2011.11.014

International Journal of Infectious Diseases
Volume 16, Issue 3 , Pages e209-e215 , March 2012

Article Tools

* Image Usage & Resolution